RxDoctor Payments Data

Nelson Yamagata, MD

Neurology · Templeton, CANPI 1821024852

Payments from drug & device makers

$1,794in general payments, 2019–2025

Across 26 payments — averaging $69.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Eisai Inc.$236
  • Amgen$223
  • Otsuka America Pharmaceutical, Inc.$30
  • Genentech USA, Inc.$29
  • Teva Pharmaceuticals USA, Inc.$29
  • plus $61 from 3 others

What the payments were for

  • Travel & lodging$66837%
  • Food & beverage$1,12663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,794 in reported general payments places this provider in the 50th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$216,973
Medicare patients
773
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5031$354,889
Aimovig AutoinjectorErenumab-Aooe28$40,382
AptiomEslicarbazepine Acetate13$27,560
QuliptaAtogepant11$11,709
Gabapentin335$9,304
Carbidopa-LevodopaCarbidopa/Levodopa214$9,263
Levetiracetam210$7,946
Ropinirole ErRopinirole Hcl46$5,990
Duloxetine Hcl140$5,877
Carbamazepine ErCarbamazepine24$4,963
Levetiracetam ErLevetiracetam41$4,417
Pregabalin70$4,201
Oxcarbazepine44$3,745
Pyridostigmine Bromide12$3,344
Lacosamide19$2,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$1,184$11,70911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,996 neurology providers in California.

Other neurology in Templeton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →